Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide

Leukemia

Volumn 26, Issue 4, 2012, Pages 855-858

  Giagounidis, A A N ^a   Kulasekararaj, A ^b   Germing, U ^c   Radkowski, R ^a   Haase, S ^a   Petersen, P ^a   Gohring G ^d   Busche G ^d   Aul, C ^a   Mufti, G J ^b   Platzbecker, U ^e  

^a ST JOHANNES HOSPITAL   (Germany)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; LENALIDOMIDE; RITUXIMAB;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROID CELL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOMODULATION; KARYOTYPE; LETTER; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; RELAPSE; REMISSION; WORLD HEALTH ORGANIZATION;

EID: 84859645925     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.268     Document Type: Letter

References (11)

1. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008; 26: 5943-5949.
2. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465. (Pubitemid 44511560)
3. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol 2005; 84: 389-394. (Pubitemid 40823353)
4. Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008; 87: 345-352.
5. Gohring G, Giagounidis A, Busche G, Kreipe HH, Zimmermann M, Hellstrom-Lindberg E et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010; 89: 365-374.
6. Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010; 363: 1025-1037.
7. Mohr B, Oelschlaegel U, Thiede C, Stewart MM, Ehninger G, Platzbecker U. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells. Haematologica 2009; 94: 430-431.
8. Göhring G, Lange K, Hofmann W, Nielsen K, Hellström-Lindberg E, Roy L et al. Short telomeres before lenalidomide treatment predict leukemic progression in patients with myelodysplastic syndrome and deletion 5q. Blood 2010; 116: 30 (abstract).
9. Jadersten M, Saft L, Pellagatti A, Gohring G, Wainscoat JS, Boultwood J et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009; 94: 1762-1766.
10. Misgeld E, Germing U, Aul C, Gattermann N. Secondary myelodysplastic syndrome after fludarabine therapy of a lowgrade non-Hodgkin0s lymphoma. Leuk Res 2001; 25: 95-98. (Pubitemid 32012986)
11. Mallo M, Cervera J, Schanz J, Such E, Garcia-Manero G, Luno E et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2010; 25: 110-120.